NASDAQ:XERS

Xeris Biopharma (XERS) Stock Price, News & Analysis

Xeris Biopharma logo
$17.09 +0.29 (+1.73%)
As of 12:27 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Xeris Biopharma Stock (NASDAQ:XERS)

Advanced

Key Stats

Today's Range
$16.75
▼
$17.28
50-Day Range
$7.45
▼
$16.80
52-Week Range
$5.25
▼
$17.28
Volume
1.05 million shs
Average Volume
2.15 million shs
Market Capitalization
$3.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00
Consensus Rating
Moderate Buy

Company Overview

Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and providing treatments for people with endocrine and other serious health conditions. Its products include Gvoke, a ready-to-use glucagon product for the treatment of severe hypoglycemia, and Recorlev, a treatment for adults with endogenous hypercortisolemia associated with Cushing syndrome when surgery is not an option or has not been curative.

The company also develops drug-delivery technologies intended to make medicines easier to store and administer. Its formulation platforms support products designed for injection, including ready-to-use and room-temperature-stable formulations.

Xeris was formerly known as Xeris Pharmaceuticals and became Xeris Biopharma Holdings following its 2021 combination with Strongbridge Biopharma. The company is based in Chicago and markets its products in the United States.

AI Generated. May Contain Errors.

Xeris Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

XERS MarketRank™: 
2.07883872686 of 5 stars

Xeris Biopharma scored higher than 42% of companies evaluated by MarketBeat, and ranked 661st out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Xeris Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside/Downside

    The consensus price target for Xeris Biopharma is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Xeris Biopharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Xeris Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Xeris Biopharma are expected to grow by 93.33% in the coming year, from $0.15 to $0.29 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Xeris Biopharma is -338.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Xeris Biopharma is -338.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Xeris Biopharma has a P/B Ratio of 62.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    5.14% of the float of Xeris Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Xeris Biopharma has a short interest ratio ("days to cover") of 4.34.
  • Change versus previous month

    Short interest in Xeris Biopharma has recently increased by 11.95%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Xeris Biopharma does not currently pay a dividend.

  • Dividend Growth

    Xeris Biopharma does not have a long track record of dividend growth.

  • News Sentiment

    Xeris Biopharma has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Xeris Biopharma this week, compared to 4 articles on an average week.
  • Search Interest

    30 people have searched for XERS on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Xeris Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Xeris Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,678,971.00 in company stock.

  • Percentage Held by Insiders

    4.35% of the stock of Xeris Biopharma is held by insiders.

  • Percentage Held by Institutions

    42.75% of the stock of Xeris Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Xeris Biopharma's insider trading history.
Receive XERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

XERS Stock News Headlines

Your $7 scanner is waiting
The Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.tc pixel
Xeris Biopharma: Time For A Pause
Analysts Issue Forecasts for Xeris Biopharma FY2026 Earnings
See More Headlines

XERS Stock Analysis - Frequently Asked Questions

Xeris Biopharma's stock was trading at $7.85 at the beginning of 2026. Since then, XERS shares have increased by 115.8% and is now trading at $16.9370.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) posted its quarterly earnings data on Thursday, November, 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.03. The business earned $107.23 million during the quarter, compared to the consensus estimate of $101.68 million. Xeris Biopharma had a negative net margin of 1.76% and a positive trailing twelve-month return on equity of 147.75%.
Read the conference call transcript
.

Xeris Biopharma (XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Mizuho Securities was co-manager.

Xeris Biopharma's top institutional shareholders include State Street Corp (3.05%), Goldman Sachs Group Inc. (0.91%), First Trust Advisors LP (0.77%) and Vilga Financial Planning LLC (0.58%). Insiders that own company stock include John Patrick Shannon Jr, Kevin Mcculloch, Steven Pieper, Beth Hecht, John Johnson, Jeffrey W Sherman, Marla Persky, Barbara-Jean A Bormann-Kennedy, Dawn Halkuff and James Aloysius Brady.
View institutional ownership trends
.

Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Xeris Biopharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Pfizer (PFE), Sorrento Therapeutics (SRNE), NIO (NIO) and Palantir Technologies (PLTR).

Company Calendar

Last Earnings
11/05/2026
Today
11/18/2026
38th Annual Healthcare Conference
12/01/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:XERS
CIK
1867096
Fax
N/A
Employees
435
Year Founded
N/A

Price Target and Rating

High Price Target
$21.00
Low Price Target
$12.00
Potential Upside/Downside
-0.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.05)
Trailing P/E Ratio
N/A
Forward P/E Ratio
58.68
P/E Growth
N/A
Net Income
$550 thousand
Net Margins
-1.76%
Pretax Margin
-1.76%
Return on Equity
147.75%
Return on Assets
6.03%

Debt

Debt-to-Equity Ratio
3.89
Current Ratio
2.15
Quick Ratio
1.58

Sales & Book Value

Annual Sales
$291.85 million
Price / Sales
10.65
Cash Flow
$0.10 per share
Price / Cash Flow
166.72
Book Value
$0.27 per share
Price / Book
63.03

Miscellaneous

Outstanding Shares
182,700,000
Free Float
174,753,000
Market Cap
$3.11 billion
Optionable
Optionable
Beta
0.61

Social Links

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NASDAQ:XERS) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners